Articles related to DEPRESSION

Emerging reports suggest some patients experience emotional blunting or reduced reward responsiveness after starting GLP-1 receptor agonists. Current evidence remains mixed, and available data have not established a causal relationship between GLP-1 therapy and diminished antidepressant response.

Natural language processing models analyzing speech from children ages 9 to 13 predicted future mental health conditions more accurately than expert-rated stress assessments. Findings suggest linguistic patterns may serve as an early risk signal, though validation in larger cohorts is still needed.

Female mice recovering from a single ketamine exposure demonstrated microglia-driven neuroplasticity through FKBP51 activation, while male mice did not. The findings identify a sex-specific biologic pathway in a preclinical model, and human relevance remains unconfirmed.

Adjunctive active VNS was associated with greater suicidal ideation improvement than sham stimulation in patients with markedly treatment-resistant depression. The exploratory analysis was not powered as a confirmatory suicide-outcomes trial.

A Phase 2 trial of luvesilocin reported rapid reductions in postpartum depression symptoms, with most treated participants reaching remission within seven days. The investigational psychedelic has received FDA Breakthrough Therapy designation, but Phase 3 confirmation remains pending.

A single dose of an investigational LSD formulation was associated with greater improvement in depressive symptoms than placebo in a phase 3 trial of adults with major depressive disorder. The findings are based on topline company-reported results and await full peer-reviewed publication.